All Articles

Future perspective of GLP-1 receptor agonists across the spectrum of steatotic liver disease

Gut microbiota in hepatocellular carcinoma: pathogenic mechanisms and clinical translation

Green tea consumption and hepatocellular carcinoma: a meta-analysis lacking evidence for a protective effect

The gut microbiome and the pathogenesis of trans-arterial chemoembolization-associated liver injury

Chronic hepatitis C and metabolic dysfunction-associated steatotic liver disease: converging pathobiology, hepatocarcinogenesis, and clinical implications in the post-SVR era

Is nicotinamide adenine dinucleotide the Achilles’ heel of chronic interleukin-6 signaling in cholangiocarcinoma?

Combining locoregional and systemic therapies in liver cancer: from strategy to survival

An immunocompetent model of hepacivirus-associated liver fibrosis and hepatocellular carcinoma

Metabolic memory and immune evasion in MASLD-HCC progression

Is the second recurrence peak in HBV-related HCC fading in the antiviral era?

Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which

Advancing immunotherapy and tumor microenvironment research in hepatocellular carcinoma

From gut-liver axis hijacking to intratumoral microbiota establishment: mechanisms and therapeutic opportunities in hepatocellular carcinoma

Beyond scarcity: rethinking transplant candidacy in the era of pig-to-human liver xenotransplantation

Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?

Evolving epidemiology and antimicrobial resistance in cirrhosis: time for a region-specific approach

Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside

Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients